Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College

Closing out their final module, expert panelists consider the role of CAR T-cell therapy in metastatic castration-resistant prostate cancer and look toward future evolutions in the broader treatment landscape.

Key opinion leaders in metastatic castration-resistant prostate cancer share insight to key ongoing clinical trials within the landscape.

Expert panelists briefly reflect on clinical trial data with CDK4/6 inhibitors in metastatic castration-resistant prostate cancer and how their role in this setting might evolve.

A broad discussion on emerging therapeutic targets in metastatic castration-resistant prostate cancer and where they may fall within the treatment landscape.

Key opinion leaders share insight to novel combination strategies and clinical trials focused on radioligand therapy in metastatic castration-resistant prostate cancer.

Continuing their segment on radioligand therapy in metastatic castration-resistant prostate cancer, panelists highlight data behind use of radium-223.

Focused discussion on the role of lutetium-177–PSMA-617 as radioligand therapy in patients with metastatic castration-resistant prostate cancer.

Key opinion leaders in metastatic castration-resistant prostate cancer management review a subset of clinical trials focused on combination strategies with PARP inhibitors.

Moving on to discuss metastatic castration-resistant prostate cancer, panelists highlight the evolving role of PARP inhibition in this setting.

Comprehensive insight to key treatment modalities for patients with nonmetastatic castration-resistant prostate cancer and how to select amongst them.

A brief conversation on negative clinical trial readouts and how they may help to inform optimal treatment pathways for patients with metastatic hormone-sensitive prostate cancer.

Following their discussion on systemic therapy, expert panelists consider the value of locoregional therapy for a subset of patients with metastatic hormone-sensitive prostate cancer.

Shared insight on the range of systemic therapy options available to patients who present with metastatic hormone-sensitive prostate cancer.

Opening their first module on metastatic hormone-sensitive prostate cancer, panelists consider optimal diagnostic and risk stratification strategies for when a patient presents in clinic.

Expert Scott Tagawa, MD, MS, FASCO, FACP, reviews recent clinical trial data on UGT1A1- and Trop-2–guided treatment of metastatic urothelial carcinoma.

Scott T. Tagawa, MD, MS, FACP, discusses integration of prostate-specific membrane antigen [PSMA] positron emission tomography [PET] imaging into community practice to help identify potential candidates for PSMA-targeted radioligand therapy.

Scott T. Tagawa, MD, MS, FACP, reviews implications for treating prostate-specific membrane antigen (PSMA) -positive advanced prostate cancer with lutetium-177–PSMA-617 based on results of the phase III VISION study and additional trials in the pipeline.

An overview of safety and efficacy data presented at ASCO 2021 from the phase III VISION study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer.

A discussion on the sensitivity and specificity of an emerging imaging modality, PSMA PET, in advanced prostate cancer.

Dr Scott T. Tagawa describes what prostate-specific membrane antigen (PSMA) is and explains its evolving role as a diagnostic, prognostic and therapeutic target in patients with advanced prostate cancer.

Scott Tagawa, MD, MS, FACP, discuses the benefits of radium-223 dichloride in prostate cancer.

Scott T. Tagawa, MD, MS, FACP, reports on data presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting regarding health-related quality of life (HRQoL) and patient-reported outcomes (PROs) at the final analysis of TITAN, a phase 3 study evaluating apalutamide versus placebo in patients with metastatic castration-sensitive prostate cancer (mCSPC) who were receiving androgen deprivation therapy (ADT).